Clinical Trials
3 trialsNCT05874414 2026-05-14
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
Genfit
Phase 1/2 Recruiting
NCT04566133 2023-08-21
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02042443 2017-09-12
S1310
National Cancer Institute (NCI)
Phase 2 Completed